Share from 0:00
0:00
/

From Lab to Exit: The TearLab Journey | Deep Tech Catalyst

Eric Donsky, founder and former CEO of TearLab, on building a MedTech company from early validation through commercialization, financing, and exit.

Welcome to the 116th edition of Deep Tech Catalyst, the educational channel from The Scenarionist where science meets venture!

In this week’s episode of Deep Tech Catalyst, I sat down with Eric Donsky, three-times exited Deep Tech entrepreneur, and today CEO of Atomic13.

In our conversation, we unpacked TearLab’s journey, a venture path at the intersection of Deep Tech and lab-on-a-chip diagnostics, from identifying an overlooked gap in eye care to building a clinically usable biomarker platform, navigating long development timelines, structuring capital around technical uncertainty, and ultimately scaling the company through clinical validation, market adoption, and the public markets.

Key takeaways from the episode:

🎯 The best opportunities often begin where demand is real but not yet explicit
Some of the most valuable Deep Tech companies are built not around markets loudly demanding innovation, but around operational or customer friction that is widespread and poorly solved.

🧩 A product must work for every user in the workflow, not just the buyer
In healthcare especially, adoption depends on solving for multiple stakeholders at once. A technology may be clinically powerful, but it still needs to fit seamlessly into the daily routines, incentives, and constraints of the people expected to use it.

🧪 The invention is only the starting point; the real challenge is building the full system
The scientific insight may define the opportunity, but commercialization depends on solving the interface between science, product architecture, manufacturability, and reliability in real-world use.

💸 In Deep Tech, capital strategy has to reflect delay, iteration, and technical risk
When timelines stretch and technical bottlenecks emerge, undercapitalization becomes one of the fastest ways to destroy optionality. The right capital often comes from investors who understand the problem deeply enough to strengthen more than just the balance sheet.

📈 Technical success does not scale on its own
Clinical evidence, trusted validators, reimbursement logic, and a credible market narrative all matter. In regulated sectors, scaling a company requires much more than proving that the technology works.


30 Execution Lessons Learned

30 Execution Lessons Learned

from 100+ Deep Tech Founders and Investors.


BEYOND THE CONVERSATION — STRATEGIC INSIGHTS FROM THE EPISODE

Keep reading. It’s free.

Join The Scenarionist community to unlock the full episode notes and key takeaways. Subscribe for free to continue reading.


Disclaimer
All materials published by The Scenarionist are provided solely for informational and educational purposes. They do not constitute financial, legal, or tax advice, nor do they constitute a recommendation, offer, or solicitation to buy or sell securities, crypto assets, or any other assets. The Scenarionist strives to provide accurate information but does not guarantee that its materials are complete, current, or free from errors, and assumes no liability for any reliance placed on them. Any external partnership or sponsored content will be clearly identified as “Brought to you by.” Unless otherwise disclosed, the companies and technologies mentioned do not sponsor The Scenarionist and are not included in its investment holdings. Artificial intelligence tools may be used for operational support and content refinement.

Ready for more?